Kintor Pharmaceutical Ltd. (9939) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Viva Biotech Holdings

Frontage Holdings Corp.

JOINN Laboratories (China) Co., Ltd.

Jacobio Pharmaceuticals Group Co., Ltd.

Sirnaomics Ltd.

Kintor Pharmaceutical Ltd.

Sinomab Bioscience Ltd.

CanSino Biologics, Inc.

Beijing Lüzhu Biotechnology Co., Ltd.

Laekna, Inc.

Ascletis Pharma, Inc.

Why is Kintor Pharmaceutical Ltd. ?

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

Poor long term growth as Net Sales has grown by an annual rate of 66.64% and Operating profit at 7.74% over the last 5 years
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -154.34

Flat results in Dec 25

DEBT-EQUITY RATIO (HY) Highest at 28.39 %
RAW MATERIAL COST(Y) Grown by 4,615% (YoY)
CASH AND EQV(HY) Lowest at HKD 38.72 MM

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 83.92%, its profits have risen by 82.5%

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Kintor Pharmaceutical Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Kintor Pharmaceutical Ltd.

83.92%

1.38

83.62%

Hang Seng Hong Kong

8.76%

0.45

19.63%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

66.64%

EBIT Growth (5y)

7.74%

EBIT to Interest (avg)

-154.34

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.05

Sales to Capital Employed (avg)

0.04

Tax Ratio

0.01%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

8.20

EV to EBIT

-10.12

EV to EBITDA

-11.49

EV to Capital Employed

7.22

EV to Sales

166.82

PEG Ratio

Dividend Yield

ROCE (Latest)

-71.30%

ROE (Latest)

-73.66%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

OPERATING CASH FLOW(Y)

Highest at HKD -400.65 MM

NET SALES(HY)

Higher at HKD 29.23 MM

NET PROFIT(HY)

Higher at HKD -127.91 MM

DEBTORS TURNOVER RATIO(HY)

Highest at 3.39 times

-7What is not working for the Company

DEBT-EQUITY RATIO (HY)

Highest at 28.39 %

RAW MATERIAL COST(Y)

Grown by 4,615% (YoY

CASH AND EQV(HY)

Lowest at HKD 38.72 MM

PRE-TAX PROFIT(Q)

Fallen at -58.55%

Here's what is working for Kintor Pharmaceutical Ltd.

Operating Cash Flow

Highest at HKD -400.65 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

Net Sales

Higher at HKD 29.23 MM

than preceding 12 month period ended Dec 2025

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (HKD MM)

Net Profit

Higher at HKD -127.91 MM

than preceding 12 month period ended Dec 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (HKD MM)

Debtors Turnover Ratio

Highest at 3.39 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Depreciation

Highest at HKD 22.5 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (HKD MM)

Depreciation

At HKD 22.5 MM has Grown at 65.5%

period on period (QoQ)

MOJO Watch

The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for Kintor Pharmaceutical Ltd.

Debt-Equity Ratio

Highest at 28.39 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Pre-Tax Profit

Fallen at -58.55%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (HKD MM)

Cash and Eqv

Lowest at HKD 38.72 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Raw Material Cost

Grown by 4,615% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales